Affiliations: [a] Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia | [b] Department of Radiotherapy, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia
Correspondence:
[*]
Corresponding author: Dr. Wala Ben Kridis, Department of Oncology, Habib Bourguiba Hospital, Sfax 3029, Tunisia. E-mail: [email protected]
Abstract: BACKGROUND:Male breast cancer (MBC) is a rare malignancy presenting only 1% of all breast cancer. The purpose of this study was to analyze clinical and pathological prognostic factors of MBC. METHODS:This is a retrospective study including 32 men diagnosed and treated for a primary breast cancer at the department of medical oncology in Sfax between 2005 and 2020. RESULTS:The incidence of MBC was 1.3%. The median age of our patients was 55 years (range: 29–85 years). The average tumor size of 3.9 cm. Lymph nodes involvement was present in 18 cases (56.2%) with capsular rupture in 52% cases. Tumor was grade II in 71.8 % of cases. The expression of hormonal receptors was founded in 100% of cases. Two patients had an overexpression of HER2 (6.2%). There was no case of triple negative MBC. The OS at 5 and 10 years was 67.8% and 30.8% respectively. Prognostic factors were T4 (p = 0.015), involved nodes (p = 0.035), M+ (p = 0.01), SBR III (p = 0.0001) and HER2+++ (p = 0.001). CONCLUSION:Contrary to breast cancer in women, our study showed that Tunisian MBC have positive hormone receptors in all cases. Although the overexpression of HER2 was low (8.33%) and there was no case of triple negative MBC, the prognosis was poor because of T4 stage, involved nodes, SBR III and distant metastases.
Keywords: Male breast cancer, survival, prognosis
DOI: 10.3233/BD-220073
Journal: Breast Disease, vol. 42, no. 1, pp. 271-275, 2023
